Briacell Therapeutics Corp

BriaCell having discussions with pharma companies on combination therapies

BriaCell Therapeutics (OTCQB: BCTXF) CEO Bill Williams sat down with Proactive Investors at the BIO CEO & Investor Conference in New York.

BriaCell is currently conducting a Phase I/IIa clinical trial of Bria-IMT, its lead candidate, in a combination study with pembrolizuma. BriaCell is also developing Bria-OTS, a personalized immunotherapy to treat advanced breast cancer.

Quick facts: Briacell Therapeutics Corp

Price: $0.06

Market: TSX-V
Market Cap: $10.8 m


e-Therapeutics’ Barlow hails deals with Novo Nordisk and ‘top five pharma...

Ray Barlow, chief executive of e-Therapeutics (LON:ETX), talks to Proactive’s Andrew Scott about the company’s unique approach to drug discovery, which uses computational techniques to find potential breakthrough new treatments. He also provided some insight into recent tie-ups with Denmark’s...

4 days, 2 hours ago

2 min read